Stay updated with breaking news from Development Highlights. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Focus on executing the strategic plan and delivering shareholder valueFirst MDG2011 pre-clinical data support potential in solid tumor therapyExpansion of patent portfolio and license agreement for...
FTI Consulting is pleased to share our third annual Corporate Sustainability Report. Within our report, we share our approach to addressing our…
Dublin, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The
Pipeline expansion into neoantigens with multiple KRAS mutations as the first targetsAcquired exclusive, worldwide rights to a CD40L-CD28 costimulatory switch proteinData from MDG1015 and multiple TCRs combined with PD1-41BB costimulatory
Phase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) enrollment target has now been surpassedAnnounced positive clinical data from the completed AQUAx Phase 1 study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX), showing bilaterally treated participants reaching normal levels of whole saliva flow rate by 2 months post-treatment and persisting through the final Month 12